News Daily News Subclinical Atherosclerosis, Dementia Entwined in People in Their 80s and Beyond Todd Neale February 29, 2016
News Daily News La Aterosclerosis Subclínica y la Demencia se Entrelazan en Pacientes Mayores de 80 Años Todd Neale February 29, 2016
News Daily News Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues Michael O'Riordan February 15, 2016
News Daily News ‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis Michael O'Riordan January 28, 2016
News Features PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data Michael O'Riordan January 25, 2016
News Daily News Low Serum Magnesium Tied to Cardiovascular Mortality, but Mechanisms Murky Todd Neale January 24, 2016
News Daily News Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond December 23, 2015
News Daily News Atherectomy Plus Angioplasty Reduces Mortality, Amputation Risk But Adds Hefty Initial Price Yael L. Maxwell December 13, 2015
News Daily News ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention Michael O'Riordan December 13, 2015
News Daily News NHANES: Just Over Half of Eligible Patients Taking Cholesterol-Lowering Medication Michael O'Riordan December 08, 2015
News Industry News Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease October 12, 2015
News Industry News Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union September 28, 2015
News Daily News Dialysis a Key Predictor of Adverse Outcomes After Endovascular Intervention for CLI L.A. McKeown August 05, 2015
News Daily News Registry Provides Reassurance About Rotational Atherectomy Pre-PCI Todd Neale July 23, 2015
News Industry News Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet July 23, 2015
News Industry News Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection July 09, 2015